Mayne Pharma and Sandoz announced a partnership for Mayne Pharma to provide Sandoz exclusive rights to promote, sell and distribute Mayne Pharma® Oxycodone IR 5 mg and Metaraminol MYX® 10 mg / 1 ml Solution for Injection Ampoules 5 in Australia.
General Manager for Mayne Pharma, Grant Swart, commented:
“Our relationship with Sandoz is aligned to our longer-term growth strategy where we will look to establish mutually beneficial relationships with our partners. Oxycodone and Metaraminol are both well-established products in the Australian market and this new agreement will ensure increased availability for patients.
We look forward to a successful long-term partnership with Sandoz to provide greater access to medicines for patients.”